{"id":"artesunate-mefloquine","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Vomiting"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Neuropsychiatric effects (mefloquine-related)"},{"rate":null,"effect":"Abdominal pain"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Artesunate, a semi-synthetic artemisinin derivative, acts as a fast-acting blood schizonticide that rapidly reduces parasite biomass through oxidative stress mechanisms. Mefloquine is a slower-acting quinoline antimalarial that concentrates in the parasite's food vacuole and prevents detoxification of heme, leading to parasite death. The combination provides complementary rapid and sustained parasite clearance with reduced risk of resistance.","oneSentence":"Artesunate kills malaria parasites by generating reactive oxygen species that damage parasite proteins and membranes, while mefloquine inhibits parasite heme polymerization and disrupts mitochondrial function.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:18:39.036Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Uncomplicated malaria caused by Plasmodium falciparum"},{"name":"Malaria treatment in endemic regions, particularly Southeast Asia"}]},"trialDetails":[{"nctId":"NCT03923725","phase":"PHASE3","title":"A Trial to Compare the Efficacy, Safety and Tolerability of Combinations of 3 Anti-malarial Drugs Against Combina-tions of 2 Anti-malarial Drugs.","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2020-09-01","conditions":"Plasmodium Falciparum Malaria (Uncomplicated)","enrollment":2583},{"nctId":"NCT05690841","phase":"PHASE3","title":"FocaL Mass Drug Administration for Vivax Malaria Elimination","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2024-10-14","conditions":"Plasmodium Vivax Malaria, Malaria","enrollment":7530},{"nctId":"NCT03939104","phase":"PHASE3","title":"A Trial to Compare the Efficacy, Safety and Tolerability of Combinations of 3 Anti-malarial Drugs Against Combinations of 2 Anti-malarial Drugs (Asia)","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2021-06-30","conditions":"Plasmodium Falciparum Malaria (Uncomplicated)","enrollment":103},{"nctId":"NCT01640587","phase":"NA","title":"Compare the Effectiveness Between Existing Treatment and New Treatment","status":"TERMINATED","sponsor":"University of Oxford","startDate":"2013-11","conditions":"P. Falciparum Malaria","enrollment":76},{"nctId":"NCT05052502","phase":"NA","title":"Targeting High Risk Populations With Enhanced Reactive Focal Mass Drug Administration in Thailand","status":"UNKNOWN","sponsor":"University of California, San Francisco","startDate":"2020-11-01","conditions":"Plasmodium Falciparum Malaria, Plasmodium Vivax Malaria","enrollment":49118},{"nctId":"NCT01054248","phase":"PHASE3","title":"Randomised Trial of 3 Artemisinin Combination Therapy for Malaria in Pregnancy","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2010-02-16","conditions":"Malaria","enrollment":511},{"nctId":"NCT00403260","phase":"PHASE3","title":"Pyronaridine - Artesunate (3:1) Versus Mefloquine Plus Artesunate in Plasmodium Falciparum Malaria Patients","status":"COMPLETED","sponsor":"Medicines for Malaria Venture","startDate":"2007-01","conditions":"Falciparum Malaria","enrollment":1271},{"nctId":"NCT03083847","phase":"PHASE1","title":"Dose Escalation PfSPZ-CVac","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2017-06-05","conditions":"Malaria","enrollment":55},{"nctId":"NCT02084602","phase":"PHASE4","title":"Assessment of Artesunate/Mefloquine in the Peruvian Amazon","status":"COMPLETED","sponsor":"Instituto Nacional de Salud. Peru","startDate":"2014-06-18","conditions":"Malaria, Falciparum","enrollment":45},{"nctId":"NCT03893097","phase":"PHASE3","title":"Evaluation of Artesunate-mefloquine as a Novel Alternative Treatment for Schistosomiasis in African Children","status":"COMPLETED","sponsor":"Institute of Tropical Medicine, Belgium","startDate":"2019-10-14","conditions":"Schistosoma Haematobium, Schistosoma Mansoni","enrollment":726},{"nctId":"NCT02653898","phase":"PHASE4","title":"Malaria Elimination Pilot Study in Military Forces in Cambodia","status":"UNKNOWN","sponsor":"Armed Forces Research Institute of Medical Sciences, Thailand","startDate":"2016-01","conditions":"Malaria, Parasitic Diseases","enrollment":1050},{"nctId":"NCT03726593","phase":"PHASE4","title":"Drug Combinations of Atovaquone-Proguanil (AP) With ACT","status":"UNKNOWN","sponsor":"Armed Forces Research Institute of Medical Sciences, Thailand","startDate":"2018-10-04","conditions":"Plasmodium Falciparum Malaria (Drug Resistant)","enrollment":252},{"nctId":"NCT02612545","phase":"PHASE1","title":"Efficacy, Safety, and Tolerability of Dihydroartemisinin-piperaquine + Mefloquine Compared to Dihydroartemisinin-piperaquine or Artesunate-mefloquine in Patients With Uncomplicated Falciparum Malaria in Cambodia","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2015-11-20","conditions":"Acute Falciparum Malaria","enrollment":216},{"nctId":"NCT02427360","phase":"","title":"Evaluating the Efficacy of Artesunate-mefloquine and the Relative Roles of Resistance Genetic Markers","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2015-05","conditions":"P. Falciparum Malaria, P. Falciparum Malaria Mixed Infection","enrollment":1022},{"nctId":"NCT00936767","phase":"PHASE2, PHASE3","title":"Artemisone for the Treatment of Uncomplicated Falciparum Malaria in Western Cambodia","status":"WITHDRAWN","sponsor":"University of Oxford","startDate":"2010-10","conditions":"Uncomplicated Falciparum Malaria","enrollment":""},{"nctId":"NCT02453308","phase":"PHASE2, PHASE3","title":"A Study by the Tracking Resistance to Artemisinin Collaboration (TRAC)","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2015-08","conditions":"Malaria, Falciparum","enrollment":1110},{"nctId":"NCT00493363","phase":"NA","title":"Clinical Investigation of In-vivo Susceptibility of P.Falciparum to Artesunate in Western Cambodia","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2007-06","conditions":"Falciparum Malaria","enrollment":40},{"nctId":"NCT01976780","phase":"PHASE4","title":"In Vivo and In Vitro Efficacy of Artemisinin Combination Therapy","status":"COMPLETED","sponsor":"Global Emerging Infections Surveillance and Response System","startDate":"2013-06","conditions":"Malaria","enrollment":118},{"nctId":"NCT02974348","phase":"PHASE3","title":"Antimalaria Drugs Susceptibility Testing for an Effective Management of Infected Patients in Sub-Sahara Africa","status":"COMPLETED","sponsor":"University of Bamenda","startDate":"2013-01","conditions":"Drug Resistant Malaria Due to Plasmodium Falciparum","enrollment":300},{"nctId":"NCT02792816","phase":"","title":"Molecular Surveillance of Artemisinin Resistance Malaria in Myanmar","status":"COMPLETED","sponsor":"Department of Medical Research, Lower Myanmar","startDate":"2009-06","conditions":"Drug Resistance, Plasmodium Falciparum Malaria","enrollment":550},{"nctId":"NCT00852423","phase":"PHASE3","title":"Safe and Efficacious Artemisinin-based Combination Treatments for African Pregnant Women With Malaria","status":"COMPLETED","sponsor":"Institute of Tropical Medicine, Belgium","startDate":"2010-06","conditions":"Malaria in Pregnancy","enrollment":3428},{"nctId":"NCT02052323","phase":"PHASE4","title":"Harmonized AS/MQ Efficacy Study - Thailand","status":"COMPLETED","sponsor":"Armed Forces Research Institute of Medical Sciences, Thailand","startDate":"2013-10","conditions":"Malaria","enrollment":48},{"nctId":"NCT01350856","phase":"PHASE4","title":"Tracking Resistance to Artemisinin (TRAC)","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2011-05","conditions":"Falciparum Malaria","enrollment":1700},{"nctId":"NCT01144702","phase":"PHASE2, PHASE3","title":"Effectiveness of the Association Artesunate and Mefloquine in the Treatment of Malaria by Plasmodium Falciparum","status":"COMPLETED","sponsor":"Oswaldo Cruz Foundation","startDate":"2010-11","conditions":"Falciparum Malaria","enrollment":163},{"nctId":"NCT01708876","phase":"PHASE3","title":"P. Knowlesi Trial of Artesunate-mefloquine Versus Chloroquine","status":"COMPLETED","sponsor":"Menzies School of Health Research","startDate":"2012-10","conditions":"Uncomplicated Plasmodium Knowlesi Malaria","enrollment":250},{"nctId":"NCT01319448","phase":"PHASE1, PHASE2","title":"Intermittent Preventive Treatment for Malaria in Patient With Sickle Cell Disease","status":"COMPLETED","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2011-09","conditions":"Malaria, Sickle Cell Crisis","enrollment":270},{"nctId":"NCT01939886","phase":"PHASE3","title":"Treatment Efficacy and Malaria TRANSmission After Artemisinin Combination Therapy 2 (TRANSACT2)","status":"COMPLETED","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2013-04","conditions":"Malaria","enrollment":219},{"nctId":"NCT00243737","phase":"PHASE2","title":"Efficacy, Safety and Pharmacokinetic of ArtequinTM P. Falciparum Malaria","status":"COMPLETED","sponsor":"Albert Schweitzer Hospital","startDate":"2005-10","conditions":"Malaria","enrollment":70},{"nctId":"NCT00164216","phase":"","title":"Efficacy and Effectiveness of Combined Therapy for Uncomplicated Malaria Treatment in Peru","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2005-03","conditions":"Malaria Falciparum","enrollment":208},{"nctId":"NCT01659281","phase":"NA","title":"Efficacy of Artesunate-Mefloquine Combination Therapy in Trat Province, Thailand","status":"COMPLETED","sponsor":"Armed Forces Research Institute of Medical Sciences, Thailand","startDate":"2007-09","conditions":"Plasmodium Falciparum Malaria","enrollment":13},{"nctId":"NCT00386750","phase":"PHASE4","title":"Safety of Artemether - Lumefantrine, and Other Malaria Drugs and Their Effect on the Auditory Function","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2005-06","conditions":"Malaria, Falciparum","enrollment":265},{"nctId":"NCT01082731","phase":"PHASE4","title":"Efficacy of Artemisinin Combination Therapies for the Treatment of Uncomplicated P. Falciparum in Pregnancy in Brazil","status":"TERMINATED","sponsor":"Centers for Disease Control and Prevention","startDate":"2010-11","conditions":"Malaria","enrollment":6},{"nctId":"NCT01107145","phase":"PHASE4","title":"Efficacy of Artemisinin Combination Therapies for the Treatment of Uncomplicated P. Vivax in Pregnancy in Brazil (PAACT-PV)","status":"TERMINATED","sponsor":"Centers for Disease Control and Prevention","startDate":"2011-02","conditions":"Plasmodium Vivax Malaria","enrollment":16},{"nctId":"NCT01082718","phase":"PHASE2, PHASE3","title":"Pharmacokinetics of Mefloquine-Artesunate in Pregnant Women With Uncomplicated Plasmodium Falciparum Infection","status":"WITHDRAWN","sponsor":"Centers for Disease Control and Prevention","startDate":"2010-03","conditions":"Malaria, Pregnancy","enrollment":""},{"nctId":"NCT00444106","phase":"PHASE4","title":"Evaluation of Potential Effect of Artemether - Lumefantrine and Malaria Drugs on Auditory Function","status":"COMPLETED","sponsor":"Novartis","startDate":"2007-05","conditions":"Malaria, Falciparum","enrollment":265},{"nctId":"NCT00701961","phase":"PHASE2, PHASE3","title":"Pharmacokinetic of Mefloquine-Artesunate in Plasmodium Falciparum Malaria Infection in Pregnancy","status":"COMPLETED","sponsor":"Institute of Tropical Medicine, Belgium","startDate":"2008-10","conditions":"Plasmodium Falciparum Malaria","enrollment":48},{"nctId":"NCT00373607","phase":"PHASE3","title":"Efficacy and Safety of Dihydroartemisinin/Piperaquine (Artekin®) for the Treatment of Uncomplicated Malaria in Peru","status":"COMPLETED","sponsor":"Institute of Tropical Medicine, Belgium","startDate":"2003-07","conditions":"Malaria","enrollment":522},{"nctId":"NCT00978172","phase":"PHASE4","title":"Safety and Efficacy Study of Artesunate and Mefloquin in Children With Uncomplicated Malaria","status":"COMPLETED","sponsor":"Mepha Ltd.","startDate":"2007-12","conditions":"Malaria","enrollment":220},{"nctId":"NCT00902811","phase":"PHASE4","title":"Effectiveness of Artemisinin Combination Regimens in Falciparum Malaria","status":"UNKNOWN","sponsor":"Medecins Sans Frontieres, Netherlands","startDate":"2008-12","conditions":"Uncomplicated Falciparum Malaria","enrollment":600},{"nctId":"NCT00544024","phase":"","title":"Mefloquine Bioequivalence Among 3 Commercially Available Tablets.","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2004-03","conditions":"Malaria","enrollment":39},{"nctId":"NCT00127998","phase":"NA","title":"Antimalarial Drug Resistance in Mali","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2005-07","conditions":"Malaria","enrollment":1011}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":196,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["ASMQ","Artesunate-Mefloquine"],"phase":"marketed","status":"active","brandName":"Artesunate + Mefloquine","genericName":"Artesunate + Mefloquine","companyName":"Armed Forces Research Institute of Medical Sciences, Thailand","companyId":"armed-forces-research-institute-of-medical-sciences-thailand","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Artesunate kills malaria parasites by generating reactive oxygen species that damage parasite proteins and membranes, while mefloquine inhibits parasite heme polymerization and disrupts mitochondrial function. Used for Uncomplicated malaria caused by Plasmodium falciparum, Malaria treatment in endemic regions, particularly Southeast Asia.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}